Nifty Pharma: how the sector's index has moved
20 companies · to the close of 2026-09-25 · chart and constituents →The sector's own line, from its companies
174 companies priced · closes adjusted for splits and bonusesBreadth, to the close of 2026-09-25: 94 of 172 companies are higher than a month ago, 104 of 142 closed above their 200-session average, 7 at a 52-week high and 4 at a 52-week low; in the last session 79 rose and 94 fell. A wide gap between the two lines means a few large companies moved the sector.
Healthcare Research, Analytics & Technology as a map
a company's area is its market value · grouped by basic industry · tinted by price changeArea is market value; the tint is the price change over the last session, full strength at 3% either way, and grey where we hold no price that far back. 6 companies. Click a company to open it.
How Nifty Pharma is priced, against its own history
NSE's daily P/E, P/B and dividend yield for the index · 10 yearsThe same as a table, by year end
| Month | P/E | P/B | Yield |
|---|---|---|---|
| Dec 2016 | 38.1 | 4.92 | 0.50% |
| Dec 2017 | 47.2 | 4.20 | 0.40% |
| Dec 2018 | 48.8 | 3.76 | 0.64% |
| Dec 2019 | 25.8 | 3.16 | 0.65% |
| Dec 2020 | 38.4 | 5.31 | 0.72% |
| Dec 2021 | 33.3 | 5.07 | 0.61% |
| Dec 2022 | 32.7 | 4.31 | 1.02% |
| Dec 2023 | 33.9 | 4.59 | 0.78% |
| Dec 2024 | 37.0 | 5.72 | 0.58% |
| Dec 2025 | 33.6 | 4.92 | 0.68% |
| Sept 2026 | 41.8 | 5.07 | 0.52% |
Nifty Pharma's own figures as NSE publishes them each day, Sept 2016 to Sept 2026 (2,478 sessions). The shaded band is where the middle half of those days sit, the dashed line their median. It says where the index has been priced, not where it should be: a multiple can be low because earnings are about to fall.
The sector's results, added up
from the companies' own quarterly filingsRevenue, added up
latest against a year before: +17.3%Net profit, added up
latest against a year before: +9.7%Q1 FY27 results
143 of 143 companies have filed · their profit together is +9.8% on the same quarter a year before (129 companies)Added up over the 119 companies that filed every quarter shown, of the 149 whose filings we hold and the 174 in the sector; each on a consolidated basis where it files one. For banks, revenue is total income. A sum is dominated by its largest companies, and says nothing about one that is not in it.
Who owns it
from the companies' quarterly shareholding patterns · weighted by market value| PPLPHARMA | 12.52% | −17.66 pp |
| ASTERDM | 10.53% | −6.65 pp |
| GAUDIUMIVF | 3.02% | −3.68 pp |
| MAXHEALTH | 41.78% | −3.61 pp |
| INDSWFTLAB | 10.70% | −3.18 pp |
| IOLCP | 4.87% | +3.15 pp |
From the shareholding patterns filed for the quarter to Jun 2026, against Mar 2026, by the 146 of 174 companies whose filings for both we hold (94% of the sector's market value), each weighted by its market value. Mutual funds and insurers are part of domestic institutions. Foreign institutions leaves out the shares a depository holds behind ADRs and GDRs, which companies file under a different head from one quarter to the next; those sit in “public and others”. “pp” is percentage points of the company's shares. A holder's share also moves when a company issues or buys back shares; these are the filed figures, not a reading of anyone's intent.
Healthcare Research, Analytics & Technology: companies
6 companies, by market value| Company | Market cap | Close | Last session | 1 year | P/E | ROE |
|---|---|---|---|---|---|---|
| Syngene International LimitedSYNGENE · Healthcare Research, Analytics & Technology | ₹15,404 Cr | ₹378.70 | −0.43% | −40.5% | 69.7 | 4.6% |
| Indegene LimitedINDGN · Healthcare Research, Analytics & Technology | ₹14,413 Cr | ₹608.95 | +2.50% | +6.5% | 36.0 | 12.8% |
| Suven Life Sciences LimitedSUVEN · Healthcare Research, Analytics & Technology | ₹9,671 Cr | ₹335.00 | −0.01% | +52.5% | — | -59.6% |
| Vimta Labs LimitedVIMTALABS · Healthcare Research, Analytics & Technology | ₹2,725 Cr | ₹599.30 | +0.30% | −20.2% | 44.4 | 17.9% |
| Bilcare LimitedBI · Healthcare Research, Analytics & Technology | ₹256 Cr | ₹100.72 | −1.99% | — | — | — |
| TAKE LimitedTAKE · Healthcare Research, Analytics & Technology | ₹235 Cr | ₹15.51 | +0.71% | +45.8% | 18.3 | 41.4% |
Closes are end-of-day, adjusted for splits and bonuses. P/E and ROE come from the last four quarters of filings, for the companies whose filings we hold. A company's sector is the one the exchanges classify it in; these are facts about the companies, not a view on the sector.